Childhood Metabolic Markers of Adult Morbidity in Blacks

NCT ID: NCT01312051

Last Updated: 2017-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

156 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-07-31

Study Completion Date

2011-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blacks are at increased risk for obesity, type 2 diabetes mellitus and cardiovascular disease. A common pathogenetic link among these entities is insulin resistance/hyperinsulinemia.

The specific aims of this project are: 1) to compare skeletal muscle lipid content (SMLC) in black vs white children by computed tomography (CT) scan of the mid-thigh, and assess the relationship to in vivo insulin sensitivity; 2) to test the hypothesis that free fatty acid (FFA) - induced insulin resistance is associated with larger increases in intramyocellular lipid (IMCL) in black vs white adolescents; 3) to examine if β-cell insulin secretion in prepubertal black children is more sensitive to the stimulatory effect of FFA than in whites; and 4) to test if the β-cell in black obese adolescents is more susceptible to the lipotoxic effect of FFA compared with whites. The methods to be used are: the well- established CT method as well as Magnetic Resonance Spectroscopy (1H-MRS) to assess SMLC and IMCL; intralipid infusion to elevate circulating FFA levels; the hyperinsulinemic-euglycemic clamp with stable isotopes and indirect calorimetry to measure insulin sensitivity and substrate turnover; the hyperglycemic clamp to assess insulin secretion; DEXA and whole body MRI for body composition assessments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Normal Weight Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protocol 1

Healthy, overweight 11 to 17 year old black and white adolescents

No interventions assigned to this group

Protocol 2

Healthy, normal-weight 11 to 17 year old black and white adolescents

No interventions assigned to this group

Protocol 3

Healthy, normal-weight 8 to 12 year old black and white adolescents

No interventions assigned to this group

Protocol 4

Healthy, overweight 11 to 17 year old black and white adolescents

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Protocols 1 \& 4:

* Age 11-17 years
* Male or Female
* Healthy
* Obese, BMI ≥ 95 percentile
* Pubertal/Tanner Stage II-V
* African American or White American, based on self identity with no admixture for 3 generations

Protocol 2:

* Age 11-17 years
* Male or Female
* Healthy
* Normal Weight, BMI 10- 95 percentile
* Pubertal/Tanner Stage II-V
* African American or White American, based on self-identity with no admixture for 3 generations

Protocol 3:

* Age 8-12 years
* Male or Female
* Healthy
* Normal Weight, BMI 10-95 percentile
* Prepubertal/Tanner Stage I
* African American or White American, based on self-identity with no admixture for 3 generations

Exclusion Criteria

* Medications which interfere with metabolism
* Hemocue \< 12 gm/dl in pubertal subjects and \<11gm/dl in prepubertal subjects
* Positive serum pregnancy test
* Recent significant weight change or dieting
* Presence of disease (i.e.diabetes, hypothyroidism, genetic dyslipidemia, etc)
Minimum Eligible Age

8 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Silva Arslanian

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HD027503

Identifier Type: NIH

Identifier Source: org_study_id

View Link